Get startedLog in
    Picture of Centessa Pharmaceuticals logo

    CNTA — Centessa Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: Centessa Pharmaceuticals Doses First Subject In Global Phase 3 Action Study Of Lixivaptan

    Picture of Centessa Pharmaceuticals logoCentessa Pharmaceuticals
    24/02/2022 12:39
    Feb 24 (Reuters) - Centessa Pharmaceuticals PLC  260y.F :
    * CENTESSA PHARMACEUTICALS DOSES FIRST SUBJECT IN GLOBAL
PHASE 3
ACTION STUDY OF LIXIVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC
KIDNEY DISEASE

Source text for Eikon:  ID:nGNX5vmcsR 
Further company coverage:  260y.F 

 ((reuters.briefs@thomsonreuters.com;))

    Recent news on Centessa Pharmaceuticals

    See all news